v3.26.1
SEGMENT REPORTING - Summary of Significant Research and Development and General and Administrative Expense to CODM (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Revenue $ 10,838 $ 29
Platform development and early-stage research expenses:    
Depreciation and amortization 299 395
Total research and development expenses 13,110 13,588
General and administrative expense    
Total general and administrative expenses 6,803 8,553
Total operating expenses 19,913 22,141
Operating loss (9,075) (22,112)
Total other (expense) income (9,366) 1,547
Net loss (18,441) (20,565)
Operating Segment    
Segment Reporting Information [Line Items]    
Revenue 10,838 29
Platform development and early-stage research expenses:    
Employee-related costs (including share-based compensation) 4,506 5,300
Laboratory supplies and services 373 538
CMOs and outsourced research and development 53 2,109
Facility-related costs, laboratory equipment, and maintenance 746 728
Depreciation and amortization 276 340
Licensing fees and other research and development costs 1,323 534
Total research and development expenses 13,110 13,588
General and administrative expense    
Employee-related costs (including share-based compensation) 3,828 5,460
Consulting and professional services 1,436 1,536
Other operating expenses and all other costs 1,539 1,557
Total general and administrative expenses 6,803 8,553
Total operating expenses 19,913 22,141
Operating loss (9,075) (22,112)
Total other (expense) income (9,366) 1,547
Net loss (18,441) (20,565)
PBGENE-HBV external development costs | Operating Segment    
Direct research and development expenses by product candidate:    
External development costs (credits) 1,835 1,601
PBGENE-DMD external development costs | Operating Segment    
Direct research and development expenses by product candidate:    
External development costs (credits) $ 3,998 $ 2,438